The Implementation of Pharmacogenomics Into Primary Care in British Columbia
Sponsor: AstraZeneca
This NA trial investigates Pharmacogenetics and is currently completed. AstraZeneca leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jun 2022 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Jun 2022 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Genome British Columbia
- GlaxoSmithKline
- Health Research Foundation
- Janssen, LP
- Merck Sharp & Dohme LLC
- Pfizer
- Roche Pharma AG
- University of British Columbia
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.